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Background: T cells have been implicated in neuropathic pain that is caused by peripheral nerve injury. Immunogenic
myelin basic protein (MBP) peptides have been shown to initiate mechanical allodynia in a T cell-dependent manner.
Antagonistic altered peptide ligands (APLs) are peptides with substitutions in amino acid residues at T cell receptor
contact sites and can inhibit T cell function and modulate inflammatory responses. In the present study, we
studied the effects of immunization with MBP-derived APL on pain behavior and neuroinflammation in an animal
model of peripheral nerve injury.
Methods: Lewis rats were immunized subcutaneously at the base of the tail with either a weakly encephalitogenic
peptide of MBP (cyclo-MBP87-99) or APL (cyclo-(87-99)[A
91,A96]MBP87-99) in complete Freund’s adjuvant (CFA) or CFA only
(control), following chronic constriction injury (CCI) of the left sciatic nerve. Pain hypersensitivity was tested by
measurements of paw withdrawal threshold to mechanical stimuli, regulatory T cells in spleen and lymph nodes were
analyzed by flow cytometry, and immune cell infiltration into the nervous system was assessed by immunohistochemistry
(days 10 and 30 post-CCI). Cytokines were measured in serum and nervous tissue of nerve-injured rats (day 10 post-CCI).
Results: Rats immunized with the APL cyclo-(87-99)[A91,A96]MBP87-99 had significantly reduced mechanical pain
hypersensitivity in the ipsilateral hindpaw compared to cyclo-MBP87-99-treated and control rats. This was
associated with significantly decreased infiltration of T cells and ED1+ macrophages in the injured nerve of
APL-treated animals. The percentage of anti-inflammatory (M2) macrophages was significantly upregulated in
the APL-treated rats on day 30 post-CCI. Compared to the control rats, microglial activation in the ipsilateral
lumbar spinal cord was significantly increased in the MBP-treated rats, but was not altered in the rats immunized
with the MBP-derived APL. In addition, immunization with the APL significantly increased splenic regulatory
T cells. Several cytokines were significantly altered after CCI, but no significant difference was observed between
the APL-treated and control rats.
Conclusions: These results suggest that immune deviation by active immunization with a non-encephalitogenic
MBP-derived APL mediates an analgesic effect in animals with peripheral nerve injury. Thus, T cell immunomodulation
warrants further investigation as a possible therapeutic strategy for the treatment of peripheral neuropathic pain.
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Peripheral nerve injury often results in neuropathic pain,
a chronic debilitating condition that adversely affects the
quality of life of sufferers. It is characterized by spontan-
eous pain and stimulus-evoked pain, including allodynia
(pain due to a stimulus which does not normally pro-
voke pain) and hyperalgesia (an increased response to a
stimulus which is normally painful) [1]. Neuropathic
pain is known to be associated with significant patho-
logical changes in the nervous system. A growing body
of evidence suggests that neuroinflammation plays a vital
role in the pathogenesis of such pain; immune cells
(such as macrophages and lymphocytes), glial cells in
the periphery and microglia and astrocytes in the spinal
cord, as well as pro-inflammatory cytokines secreted by
these cells, have all been implicated [2-4]. In particular,
recent studies have demonstrated that T cells contribute
to neuropathic pain following nerve injury [5,6].
T cells are one of the major cellular components of the
adaptive immune response. They are a heterogeneous
group, divided into helper T (Th) cells, cytotoxic T cells,
and regulatory T (Treg) cells, with several subpopula-
tions of each type. T cells are almost absent in the intact
nervous system tissue. Following peripheral nerve injury,
T cells infiltrate the injured nerve [6,7], the dorsal root
ganglia (DRGs) [8,9], and the spinal cord [5,8,10]. Athy-
mic nude rats that lack mature T cells [6], nude and
CD4-knockout mice [10], and T cell-deficient Rag1-null
mice [5] display reduced neuropathic pain behaviors.
The precise role of specific T cell subsets in neuropathic
pain remains unclear, but at least in part depends on
their distinctive cytokine profile. The phenotype of
spinal cord-infiltrating CD4+ T cells has been character-
ized as a pro-inflammatory Th1 subtype in a murine
model of neuropathic pain [11]. Th1 cells producing
pro-inflammatory cytokines such as interferon-γ (IFN-γ)
and Th17 cells producing the pro-inflammatory cytokine
IL-17 have been shown to contribute to neuropathic
pain hypersensitivity [5,6,12]. In contrast, Th2 cells pro-
ducing anti-inflammatory cytokines (e.g., interleukin; IL-
10) have been shown to attenuate pain hypersensitivity
[6]. Furthermore, expansion of immunosuppressive Treg
cells by treatment with CD28 superagonist decreased,
whereas suppression of Treg cells by anti-CD25 antibody
treatment increased mechanical allodynia following per-
ipheral nerve injury [13]. Thus, modulation of the T cell
immune response in the nervous system may be useful
in the management of chronic neuropathic pain.
Altered peptide ligands (APLs) (also known as mutant
or antagonist peptides) are analogs derived from the ori-
ginal antigenic peptide that commonly carry a single or
more amino acid substitutions at T cell receptor (TCR)
contact residues. Engagement of the TCR by such APLs
usually impairs normal T cell function [14]. Thus, someAPLs are able to specifically antagonize and inhibit T
cell activation induced by the wild-type antigenic peptide
[15]. APLs have been shown to modulate the immune
response both in vitro and in vivo by different cellular
mechanisms including mediating partial agonism, antag-
onism and T cell anergy [16], shifting immune responses
from Th1 to Th2 [17], down-regulation of pro-
inflammatory cytokines (e.g., tumor necrosis factor; TNF
and IFN-γ) and up-regulation of anti-inflammatory cyto-
kines (e.g., IL-4, IL-10, and tumor growth factor-β)
[18,19], and bystander suppression by induction of pro-
tective Treg cells [20]. Indeed, APLs have been used as
immunotherapeutics in autoimmune diseases, infectious
diseases, and cancer [15]. For example, APLs derived
from proteins of the myelin sheath are used in experi-
mental autoimmune encephalomyelitis (EAE), a chronic
demyelinating autoimmune disease of the central nervous
system which serves as an animal model of multiple scler-
osis (MS). Immunization with immunodominant epitopes
of myelin basic protein (MBP) or myelin proteolipid pro-
tein (PLP) induces EAE. In the last two decades, many
studies in rodents have demonstrated that several MBP-
or PLP-derived APLs confer protection from the develop-
ment of EAE and even reverse established paralytic disease
[16,18,21]. These APLs were shown to induce T cells that
are cross-reactive with the native myelin peptide, but
modify the immune response and prevent autoimmune
encephalomyelitis.
In this study, we chose to use a MBP-derived APL.
MBP is a major constituent of the myelin sheath of oli-
godendrocytes and Schwann cells in the nervous system
and is considered to be a key auto-antigen in inducing T
cell activation in MS and EAE [22,23]. We have previ-
ously demonstrated that active immunization with
MBP-derived APL in an animal model of EAE not only
mitigated the disease course but also improved symp-
toms of mechanical pain hypersensitivity in rats [24]. In
addition, recent studies have shown that immunization
with MBP-derived APL significantly protected from
neuronal loss and promoted recovery after incomplete
spinal cord injury [25] and ameliorated depressive be-
havior in an animal model of depression [26] by pro-
voking a protective immune response. Furthermore,
exposure of immunodominant MBP peptide epitopes
by proteolysis of myelin via matrix metalloproteinases
in the injured nerve induced mechanical allodynia in
both a T cell-dependent and independent manner
[27,28]. Considering that MBP peptides are able to ini-
tiate mechanical hypersensitivity [28] and that MBP-
derived APLs can modulate the MBP-specific T cell
immune response, we studied the effects of immunization
with MBP-derived APL on pain hypersensitivity, immune
cell reactivity, prevalence of regulatory T cells, and cyto-
kine expression profile in neuropathic animals following
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widely accepted animal model of peripheral neuropathy.
Methods
Animals
Male Lewis rats 8 to 10 weeks old were used in all ex-
periments (Animal Resource Centre, Perth, WA,
Australia). The rats were group-housed with water and
food ad libitum and maintained on a 12:12 h light/dark
cycle. The facility was kept at a constant room
temperature and humidity level, and the animals were
monitored daily throughout the experiments. All experi-
ments in animals were approved by the Animal Care
and Ethics Committee of the University of New South
Wales, Sydney, Australia and performed in compliance
with guidelines issued by the International Association
for the Study of Pain.
Chronic constriction injury of the sciatic nerve
The rats were anesthetized with 5% isofluorane (Delvet
Pty Ltd., Seven Hills, NSW, Australia) and were main-
tained with 2% to 3% of isoflurane in oxygen. The sur-
gical site was aseptically prepared, and CCI was
performed on the left sciatic nerve (LSN) according to
the protocol of Bennette and Xie [29]. Briefly, the thigh
skin was incised, the connective tissue between the
gluteus superficialis and the biceps femoris muscles was
cut, and the left sciatic nerve was exposed and freed.
Four loose ligatures were tied around the nerve using
chromic gut sutures (4-0 Ethicon, Somerville, NJ, USA),
proximal to the trifurcation without arresting the
epineural blood flow. In the sham-operated rats, the
nerve was exposed but not ligated. The muscle layers
and subcutaneous tissue was sutured with 5-0 silk
(Mersilk, Ethicon, Somerville, NJ, USA) and the incision
was closed with staples (9 mm, Autoclips, BD Diagnos-
tic, North Ryde, NSW, Australia).
Immunization and animal monitoring
Following CCI or sham operation, the rats were immu-
nized subcutaneously at the base of the tail (on day 0;
D0) with either 200 μl of complete Freund’s adjuvant
(CFA; as control; n = 6) or 200 μl of APL (250 μg cyclo-
(87-99)[A91, A
96]MBP87-99 in CFA; n = 6) or 200 μl of
MBP (250 μg Cyclo-MBP87-99 in CFA; n = 6). CFA was
prepared by mixing 1 mg/mL Mycobacterium tubercu-
losis (strain 37A, Difco Laboratories, Detroit, MI, USA)
in incomplete Freund’s adjuvant (Difco Laboratories,
Detroit, MI, USA). Since intraplantar administration of
CFA by itself can cause inflammatory pain at the
injected paw and spinal glial activation [30], we immu-
nized animals at the base of the tail. We cannot exclude
the possibility of potential effects of the CFA vehicle on
pain sensitivity and neuroinflammation in our immunizedrats; however, this effect would be evident in all groups.
MBP87-99 was used as the native peptide control based on
its weakly encephalitogenic property [31] and its potential
ability to initiate neuroinflammation and pain on its own
[28]. Previous studies using site-directed mutagenesis to
compare different mutant peptides have shown that the
peptide MBP87-99 with double Ala mutations at positions
91,96-[A91,A96]MBP87-99 alters immune responses leading
to decreased EAE severity [32]. Our study was designed to
assess the effects of this mutant peptide on pain sensitivity
in the nerve-injured rats. In addition, cyclic peptides have
been shown to be more stable than their linear counter-
parts in vivo [23]. Thus, for increased stability, the pep-
tides were cyclized from head to tail. Both cyclo-MBP87-99
and cyclo-(87-99)[A91, A
96]MBP87-99 were custom synthe-
sized (Mimotopes Pty Ltd., Clayton, VIC, Australia). Fol-
lowing CCI and immunization, the rats were monitored
daily for clinical signs of EAE for 4 weeks using a scale
ranging from ‘0’ being clinically normal to ‘5’ being paraly-
sis of all limbs (quadriplegia).
Pain hypersensitivity testing
Animals were acclimatized to the pain behavioral testing
apparatus for 1 h prior to the initial testing in a quiet
and well-controlled environment. Thereafter, tests were
carried out twice a week, after habituating the animals
in the apparatus for at least 30 min. Baseline data prior
to surgery and up to 4 weeks post-surgery were collected
for mechanical withdrawal thresholds in hindpaws. The
rats were placed in a perspex test cage on an elevated
mesh, and the mid-plantar surface of the hindpaws was
stimulated with a dynamic von Frey anesthesiometer
(Ugo Basile, Comero, Italy). This device lifts a filament
to mechanically stimulate the hindpaw with an increas-
ing force by applying pressure to the paw, and upon
withdrawal reaction, the system automatically records
and displays the maximum force applied (in grams). The
left and right hindpaws were tested three times in each
testing session with a 3- to 5-min interval, and then the
average per each paw was calculated.
Immunohistochemistry
The rats were killed and tissues were removed for im-
munohistochemistry at day 10 and day 30 post-CCI.
Each rat was injected with sodium pentobarbital and
perfused with heparinised saline (0.9% NaCl) followed by
4% paraformaldehyde (PFA). Left and right sciatic
nerves, left and right L4 and L5 DRG, and lumbar spinal
cords (segment L4-L6) were dissected and post-fixed in
4% PFA overnight at 4°C and then transferred to 30% su-
crose + 0.1% sodium azide solution and stored at 4°C
until sectioning. Sciatic nerves and DRGs were cryosec-
tioned longitudinally (10 μm thick), while spinal cords
were sectioned coronally (20 μm thick). Sections were
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dried, and stored at −20°C until use.
For staining, slides were first incubated with 100%
ethanol for 10 min at room temperature followed by two
washes with dH2O for 5 min each. After washing with
phosphate-buffered saline (PBS) for 3 min, sections were
blocked for 30 min at room temperature with PBS con-
taining 0.05% Tween 20 and 5% normal donkey serum
(Jackson Immune Research, Westgrove, PA, USA). For
TCRαβ staining, sections were incubated with acetone
for 3 min and washed with PBS three times prior to add-
ing the blocking solution. Sciatic nerve and DRG sec-
tions were incubated with the following primary
antibodies diluted in PBS containing 5% bovine serum
albumin (Sigma-Aldrich, Sydney, Australia) and 0.05%
Tween-20 for 1 h at room temperature: for T cells with
mouse anti-rat TCRαβ (1:250, clone R73, BD Bioscience,
San Jose, CA, USA), and for monocytes and macro-
phages with mouse anti-rat CD68 (1:250, clone ED1;
Serotec, Raleigh, NC, USA). Spinal cord sections were
incubated for 1 h at room temperature with rabbit anti-
rat ionized calcium binding adaptor molecule 1 (Iba-1,
1:2000; Wako Chemicals USA, Richmond, VA, USA) for
microglia/macrophages and mouse anti-rat glial fibrillary
acidic protein (GFAP; 1:2000, Chemicon, Temecula, CA,
USA) for astrocytes in PBS containing 5% BSA, 0.05%
Tween-20, and 0.05% Triton-X, or overnight at 4°C with
mouse anti-rat TCRαβ (1:250) in PBS (with 5% BSA and
0.05% Tween-20). For double staining of M1 and M2
macrophages, sciatic nerves were stained for M1 macro-
phages with mouse anti-rat CD68 (1:250, clone ED1;
Serotec) and rabbit anti-iNOS (1:1000; Abcam, Cambridge,
UK). For M2 macrophages, the sections were stained with
anti-Iba-1 (1:2000; Wako Chemicals USA) and mouse anti-
mouse/rat Arginase-1 (1:100, clone 19; BD biosciences)
and incubated at 4°C overnight. Then, the sections
were rinsed four times in PBS and incubated for 1 h
with the secondary antibodies, Alexa Fluor 488 conju-
gated donkey anti-mouse (1:250, Jackson Immuno
Research Laboratories) or Cy3 conjugated donkey anti-
rabbit (1:400, Jackson Immuno Research Laboratories)
in the same buffer as the primary antibody. The sec-
tions were rinsed again four times in PBS, and prolong
gold anti-fade reagent with 4', 6-diamidino-2-phenylindole
(DAPI) (Life Technologies, Mulgrave, VIC, Australia) was
then applied prior to slides being cover slipped.
Immunofluorescent image analysis
Slides were visualized with an Olympus fluorescence
microscope and images captured using an Olympus
DP73 camera and DP Controller software (Olympus,
Tokyo, Japan). For each animal, slides containing each of
four sciatic nerve sections, four DRG sections, and six
spinal cord sections (rostro-caudal) were stained for agiven antibody. In the injured sciatic nerve sections, six
images were captured (two at site of injury, two at prox-
imal to the injury, and two at distal to the injury) per
section (total 24 images per slide/animal). For DRGs,
four images were taken from areas containing cell bodies
in each section (four sections/slide). For spinal cord, im-
ages of the dorsal horn and ventral horn were taken
from both ipsilateral and contralateral sides of six differ-
ent L4-L6 coronal sections per slide. All images were
captured at × 20 magnification. The cells were then ei-
ther counted manually (TCR αβ) using the cell counter
plug-in, or where their numbers were too numerous,
were analyzed by densitometry (ED1, GFAP, and Iba-1)
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). Densitometry measurements were
made by adjusting the threshold of the images to ex-
clude nonspecific fluorescence and measuring the per-
centage of immune positive areas. Cell counts or
densitometry measurements from each image analyzed
were averaged for each region for each animal. These
data were plotted as the average of three to four rats of
cell count or percentage area of immunoreactivity. Six
images from each slide were captured from sections
stained for M1 and M2 macrophages along the sciatic
nerve section. Images were taken where the maximum
number of positively stained cells presented at × 10 mag-
nification, and cells were counted manually using
ImageJ.
Cell isolation and flow cytometry
Flow cytometry was performed with tissues collected on
days 10 and 30 post-CCI. The nerve-injured rats were
deeply anesthetized with isoflurane, and popliteal and in-
guinal lymph nodes and spleen were collected in PBS.
Each tissue was processed separately to achieve single
cell suspensions by pressing the spleen and lymph nodes
through a 40-μm cell strainer (BD Bioscience, Franklins
Lakes, NJ, USA) in PBS. Cell suspensions were centri-
fuged for 4 to 5 min at 800 × g at 4°C before discarding
the supernatant. Red blood cell lysis was performed for
spleen samples by re-suspending cells in Red Blood Cell
Lysis Buffer (eBioscience, San Diego, CA, USA) for 4 to
5 min with occasional shaking. Cell suspensions were
first washed in PBS, with a second wash in Roswell Park
Memorial Institute (RPMI) media (Invitrogen, Mulgrave,
VIC, Australia). The cells were incubated at 37°C in
RPMI/10% fetal bovine serum (Invitrogen) for 1 h to
allow adherence and removal of monocytes. Following
incubation, the cells were counted and re-suspended in
flow cytometry staining buffer (eBioscience). Cell surface
markers were stained for 30 min at 4°C, with the follow-
ing combinations of antibodies: mouse anti-rat CD4-
FITC (eBioscience) and mouse anti-rat CD25-APC
(eBioscience) or suitable isotype controls. Then cells
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Biotec, San Diego, CA, USA) before being fixed over-
night at 4°C with fixation/permeabilisation solution
(eBioscience). The samples were then washed twice with
permeabilisation buffer (eBioscience) and stained with rat
anti-mouse/rat Foxp3-PE or isotype control antibodies in
permeabilisation buffer for 30 min at 4°C. Finally, samples
were washed three times with permeabilisation buffer and
re-suspended in MACS buffer (Miltenyl Biotec, San Diego,
CA, USA). The cells were then acquired and analyzed on
a BD FACS CantoII flow cytometer and BD FACS DIVA
software (BD Biosciences). A minimum of 100,000 events
was acquired for each sample.
Serum preparation, protein purification/quantification,
and cytokine assay
The rats were deeply anesthetized with isoflurane and
1 mL of blood was collected from the left ventricle of
the exposed heart at day 10 post-CCI. Sodium pentobar-
bital was then injected i.p. and animals subsequently
perfused with heparinised saline. Sciatic nerves, DRGs,
and spinal cords were collected and flash-frozen in li-
quid nitrogen before being stored at −80°C until pro-
cessing. Serum was separated from collected blood by
allowing clotting at 37°C for 1 h, followed by centrifuga-
tion at 400 × g for 20 min. The supernatant was then
collected, and aliquots were stored at −80°C.
Nervous tissue was mechanically dissociated on ice
with protease inhibitor and TM buffer (Total protein ex-
traction kit from Millipore, Billerica, Massachusetts,
USA) according to the manufacturer’s instructions and
homogenized with Precelly’s homogenizer in 2.8 mm cer-
amic bead tubes (Geneworks, Hindmarsh, SA, Australia)
twice for 20 s each time. Homogenized tissue was rotated
at 4°C for 20 min and centrifuged at 13,000 × g at 4°C for
20 min. Supernatants were collected, and proteins were
quantified using the EZQ protein quantification kit
(Molecular probes/Life technologies, Mulgrave, VIC,
Australia) according to the manufacturer’s instructions.
Serum and protein samples of sciatic nerves, DRGs,
and spinal cord were used for cytokine and chemokine
analysis using the Bio-Plex Pro Rat Cytokine 23-plex
Assay kit on a Bio-Rad Bio-plex machine (Bio-Rad
Laboratories, Hercules, CA, USA). Serum samples, di-
luted at 1:4 dilution with sample diluent, and protein
samples prepared to a concentration of 25 μg/50 μL,
were analyzed per the manufacturer’s instructions.
Experimental design and statistical analysis
Details of the experimental design used to determine the
effects of immunization on neuropathic pain and neuro-
inflammation are described in Figure 1. Following CCI/
sham surgery, animals were randomly allocated to treat-
ment groups and immunized and tested for painhypersensitivity over 27 days. The number of animals
used was n = 6 per group for pain measurements, n = 4
to 7 per group for cytokine assay, and n = 3 to 4 per
group for immunohistochemistry and flow cytometry
based on previous studies [6,12,13,28,33]. Tissue har-
vesting was carried out at days 10 and 30 post-CCI. Day
10 was chosen since pain hypersensitivity is well-
established by day 10 after nerve injury and since we ob-
served high withdrawal thresholds in the APL-treated
rats with most significant differences between the groups
on that day. At around 27 days after injury, the effects of
immunization on pain responses started to decline, and
therefore, day 30 was used as the end point of our ex-
periment. The uninjured contralateral nerves and the
contralateral side of the DRGs and spinal cords were
used as internal controls in immunohistochemistry ana-
lysis, and serum and nervous tissues from naïve unin-
jured animals were used as controls in cytokine assays.
Statistical analysis was performed using Graphpad prism
6.0 software. Behavioral results were analyzed by two-way
repeated measure analysis of variance (RM-ANOVA)
followed by Tukey’s multiple comparisons post-test. Im-
munohistochemistry results and flow cytometry results
were analyzed by two-way ANOVA with Tukey’s multiple
comparison test. One-way ANOVA was used to analyze
cytokine assay results with Dunnet’s multiple compari-
son test and multiplicity adjusted P values. P ≤ 0.05 was
considered as statistically significant.
Results
Immunization with cyclo-(87-99)[A91, A
96]MBP87-99
significantly decreased mechanical allodynia in the
ipsilateral hindpaw of the nerve-injured rats
To investigate the effects of immunization with myelin-
derived APL on pain hypersensitivity, we carried out
CCI of the sciatic nerve followed by immunization with
MBP87-99 (native peptide), APL cyclo-(87-99)[A
91
, A
96]
MBP87-99, and CFA only (vehicle control). Pain testing
was carried out on both ipsilateral and contralateral
hindpaws of the nerve-injured and sham-operated rats
for 4 weeks post-surgery. The animals immunized with
the MBP-derived APL demonstrated significantly de-
creased mechanical pain hypersensitivity in the left hind-
paw compared to the MBP-treated and CFA-treated rats
starting from day 6 until day 24 post-CCI (Figure 2A),
with the most significant difference observed on days 8
(P < 0.001), 10 (P < 0.01), 20 (P < 0.0001), and 23 (P < 0.01)
post-CCI. For example, on day 20, the APL-treated rats
demonstrated a withdrawal threshold of 21.8 ± 4.1 g in the
ipsilateral hindpaw, as compared to CFA-treated and
MBP-treated rats, which had thresholds of 7.6 ± 0.6 and
11.8 ± 1.5 g, respectively. Nerve-injured rats started to de-
velop pain hypersensitivity as early as 3 days after the in-
jury. During the testing period, APL-treated rats’ paw
Figure 1 A scheme of the experimental paradigm. Male Lewis rats underwent CCI of the left sciatic nerve or sham operation on day 0
followed by subcutaneous immunization at the base of the tail. They were tested for pain hypersensitivity for 4 weeks (n = 6/group). On 10 and
30 days post-CCI, sciatic nerves (SNs), DRGs, and spinal cords (SCs) were collected for immunohistochemistry (n = 4/group) and spleens and lymph
nodes for flow cytometry. For cytokine assay, SNs, DRGs, SCs, and serum were isolated from nerve-injured rats at 10 days post-CCI and from naïve
rats (n = 6 to 7/group).
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tween 15 and 22.5 g, whereas with the MBP-treated and
control rats, the maximum withdrawal threshold did not
exceed 11.8 g at any time point. There were no differences
between groups in mechanical pain sensitivity in theFigure 2 Immunization with cyclo-(87-99)[A91,A96]MBP87-99 significant
(A-D) Time course of mechanical withdrawal threshold of the hindpaws (in
(native peptide), APL cyclo-(87-99)[A91, A
96]MBP87-99 and CFA only (vehicle c
of the rats with CCI and (C) ipsilateral hindpaw and (D) contralateral hindpaw
represent significant differences between the MBP- and APL-treated rats, *(P <
differences between the APL-treated and control rats. #(P < 0.05) and ##(P < 0.0
(n= 6 per group; mean ± SEM; two-way RM-ANOVA with Tukey’s multiple compcontralateral hindpaws (Figure 2B). We also examined the
effect of immunization in the sham-operated rats. Interest-
ingly, at several time points during the experiment, the
sham-operated rats treated with MBP demonstrated
elevated and statistically significant mechanical painly decreases mechanical pain hypersensitivity following CCI.
grams) in nerve-injured and sham-operated rats treated with MBP87-99
ontrol) in (A) the ipsilateral hindpaw and (B) the contralateral hindpaw
of the sham-operated rats. +(P < 0.05), ++(P < 0.01), and +++(P < 0.001)
0.05), **(P < 0.01), ***(P < 0.001), and ****(P < 0.0001) indicate significant
1) represent significant differences between MBP-treated and control rats
arison test). Arrows indicate the time point of CCI/sham and immunization.
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and CFA-treated (P < 0.01) sham rats in both ipsilateral
(Figure 2C) and contralateral (Figure 2D) hindpaws.
Nerve-injured rats did not develop significant thermal pain
hypersensitivity, and therefore, no effects of immunization
on thermal hyperalgesia were observed (data not shown).
Further, animals immunized with either MBP or APL did
not develop any sign of clinical EAE during the experimen-
tal period.
Immunization with cyclo-(87-99)[A91, A
96]MBP87-99
significantly reduced T cell infiltration to the injured
sciatic nerve at 10 days post-CCI
T cells have been implicated in neuropathic pain [6] and
MBP-derived APLs have been shown to modulate T cell
responses in animal models [32]. Immunostaining for
TCRαβ was performed on histological sections of the left
and right sciatic nerves, L4 and L5 DRGs, as well as in
the corresponding region of the lumbar spinal cord dis-
sected at days 10 and 30 post-CCI and immunization.
We found a significant reduction in T cell numbers in
the injured sciatic nerve in rats treated with cyclo-(87-99)
[A91, A
96]MBP87-99, as compared to CFA-treated rats at
10 days post-CCI (Figure 3). T cell numbers were signifi-
cantly increased in the CFA control group on 10 days
post-CCI (Figure 3A) and in the MBP-treated group on
30 days post-CCI (Figure 3B) at the site of injury. On
10 days post-CCI, the T cell numbers at the site of injury
were 90.2 ± 31.8 (CFA-treated; Figure 3H), 59.3 ± 15.0
(MBP-treated; Figure 3I), and 40.4 ± 3.8 (APL-treated;
Figure 3J), representing a significant difference between
CFA and APL groups (P < 0.01). Further, in the APL-
treated group, the T cell counts proximal and distal to
the injury were also lower than the other two groups at
10 days post-CCI, although the difference was not sta-
tistically significant (Figure 3A). On day 30 post-CCI
(Figure 3B), the T cell numbers at the site of injury had
sharply increased in the MBP-treated group (224.8 ±
36.6) compared to that on day 10 post-CCI (59.3 ± 15.0;
P < 0.001). Further, APL-treated and control rats
showed significantly lower (P < 0.0001) T cell count at
the injured site (CFA = 61.9 ± 19.6 and APL = 93.2 ± 19)
compared to MBP-treated group, but there was no signifi-
cant difference in T cell count between the APL-treated
and the control group at 30 days post-CCI. There was no
significant difference between treatment groups at the
proximal or distal to the injury site at day 30 post-CCI. Al-
most no T cells were found in the contralateral nerve at
any time point in any of the treatment groups (Figure 3A-
B,G). T cell infiltration to L4-L5 DRGs (Figure 3C-D) and
dorsal and ventral horns of the spinal cord (Figure 3E-F)
was comparatively very low compared to those of the in-
jured sciatic nerve, and no significant differences were
found between the groups.Immunization with cyclo-(87-99)[A91, A
96]MBP87-99
significantly reduced ED1+ macrophage infiltration to
the injured sciatic nerve
Macrophages have also been shown to contribute to
neuropathic pain behavior in animal models [34-36].
Thus, we stained injured and uninjured sciatic nerves
with ED1, a generic macrophage marker, to investigate
the effects of immunization on macrophage infiltration
following nerve injury. We analyzed the percentage of
ED1+ immunoreactivity at the site of injury, proximal to
the injury and distal to the injury at 10 and 30 days
post-CCI (Figure 4). Immunization with APL cyclo-
(87-99)[A91, A
96]MBP87-99 led to a significantly de-
creased percentage of ED1+ cells in the injured nerve
(Figure 4A-B,F) in contrast to MBP-treated (Figure 4
A-B,E) and CFA-treated rats (Figure 4A-B,D). At
10 days post-CCI, immunization with the APL signifi-
cantly decreased ED1+ macrophages compared to
CFA-treated rats (P < 0.05) at the site of injury and
compared to MBP-treated rats (P < 0.05) distal to the in-
jury (Figure 4A). At 30 days post-CCI, APL immunization
significantly reduced ED1+ cell reactivity proximal to the
injury (P < 0.05), at the site of injury (P < 0.0001) and distal
to the injury (P < 0.0001) compared to the control and
MBP-treated rats (Figure 4B). Macrophages were found in
the contralateral nerve in small numbers; however, there
were no significant differences between treatment groups
(Figure 4A-C).
Immunization with cyclo-(87-99)[A91, A
96]MBP87-99
significantly increased M2 macrophages in the injured
nerve at day 30 post-CCI
Recently, several functional phenotypes of macrophages
have been demonstrated, such as the M1/M2 paradigm
comprised of pro-inflammatory (M1-polarized) and al-
ternatively activated (M2-polarized) macrophages [37].
However, the activation of different subsets of macro-
phages following CCI has not been studied. Here, we
double stained the injured sciatic nerves with ED1/iNOS
(M1-like macrophages) and Iba-1/Arginase (M2-like
macrophages) to investigate the effects of immunization
with cyclo-(87-99)[A91, A
96]MBP87-99 on M1/M2 macro-
phage expression following CCI. ED1+ and Iba-1+ cells
were distributed all along the nerve either as clusters of
cells or free standing cells; however, the distribution of
double-stained cells was somewhat different. ED1+
iNOS+ cells (Figure 5A) were mainly located in the le-
sion itself or peri-lesion area as free-standing cells. In
contrast, Iba-1+ Arginase + cells (Figure 5B) were found
in the intact nerve, periphery, or peri lesion area either
as cell clusters or single cells.
The percentages of M1-like macrophages were com-
paratively low at 10 days post-CCI in all treatment
groups ranging from 10 to 15% of ED1+ cells, but were
Figure 3 (See legend on next page.)
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Figure 3 Immunohistochemistry of T cells in the sciatic nerve, DRGs, and spinal cord. The number of TCRαβ immunoreactive cells at the
site of injury, proximal to the injury and distal to the injury in the left sciatic nerve (LSN) and uninjured right sciatic nerve (RSN) at 10 days (A) and
30 days (B) post-CCI. The number of TCRαβ immunoreactive cells in the L4 and L5 ipsilateral DRG (L-DRG) and contralateral DRG (R-DRG) at
10 days (C) and 30 days (D) post-CCI. The number of TCRαβ immunoreactive cells in the ipsilateral (left) and contralateral (right) lumbar spinal
cord at 10 days (E) and 30 days (F) post-CCI. ##P < 0.01 represents a significant difference between the APL-treated and control rats at the site of
injury at 10 days post-CCI in the LSN. ****P < 0.0001 denotes significant differences between MBP-treated rats as compared to the APL-treated
and control rats at 30 days post-CCI at the site of injury (n = 4 per group; mean ± SEM; two-way ANOVA with Tukey’s multiple comparison test).
Representative images of (G) T cells in the uninjured nerve, (H) T cells in control, (I) T cells in MBP-treated and (J) T cells in APL-treated LSN at
the site of injury. Scale bar = 50 μm.
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APL-treated groups (to approximately 30%; Figure 6A).
However, a statistically significant difference was not seen
between the treatment groups. At 10 days post-CCI, the
percentage of Iba-1+ Arginase + cells was around 40% in
all groups (Figure 6B). Interestingly, at 30 days post-CCI,
the APL-treated group had a significantly increased
(P < 0.05) Iba-1+ Arginase + (M2) cell percentage com-
pared to other treatment groups (Figure 6B).Figure 4 Immunohistochemistry of ED1+ macrophages in the sciatic
to the injury and distal to the injury in the left sciatic nerve (LSN) and right un
represents significant difference between APL-treated and control rats at
distal to the injury at 10 days post-CCI. At 30 days post-CCI, *P < 0.05 rep
and +P < 0.05 between MBP and APL group proximal to the injury. ****P
control group, ++++P < 0.0001 between MBP and APL group at the site of inju
with Tukey’s multiple comparison test). Representative images of (C) ED1+ ce
in MBP-treated, and (F) ED1+ cells in the APL-treated LSN at the site of injury.Effects of immunization on glia activation in the lumbar
spinal cord
It has been shown that in models of peripheral nerve in-
jury, the glial cells in the spinal cord become activated
and contribute to the development of neuropathic pain
[13]. Spinal cord sections were stained with Iba-1 to de-
tect activation of resident microglia and infiltrated mac-
rophages and with GFAP to detect activated astrocytes
in the spinal cord following CCI and immunizationnerve. The average of ED1+ area density at the site of injury, proximal
injured nerve (RSN) at 10 days (A) and 30 days (B) post-CCI. *P < 0.05
the site of injury and +P < 0.05 between MBP- and APL-treated rats
resents significant difference between the APL and control group
< 0.0001 represents significant differences between the APL and
ry and distal to the injury; (n= 4 per group; mean ± SEM; two-way ANOVA
lls in uninjured RSN, (D) ED1+ cells in CFA-treated control, (E) ED1+ cells
Scale bar = 50 μm.
Figure 5 Immunohistochemistry of M1- and M2-like macrophages in the injured nerve. Representative immunofluoroscent images of triple
labeled cells for (A) ED1+ (green) iNOS+ (red) DAPI (blue) and (B) Iba-1+ (red) Arginase-1+ (green) DAPI (blue) cells at the site of injury in the
LSN. Scale bar = 100 μm.
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immunoreactivity in the MBP-treated group compared to
the other groups on day 30 (Figure 7B) but not on day 10
(Figure 7A) post-CCI in the ipsilateral dorsal and ventral
horn of the spinal cord. In the left dorsal horn, the MBP-
treated rats (Figure 7B,F) exhibited significantly increased
microglia activation compared to the CFA group (Figure 7
B,E; P < 0.01) and APL group (Figure 7B,G; P < 0.0001).
Similarly, significant differences were seen in the left ven-
tral horn between the MBP-treated group and CFA-
treated group (P < 0.05), as well as the MBP-treated and
APL-treated groups (P < 0.01) on 30 days post-CCI. How-
ever, no significant differences in Iba-1 immunoreactivity
were found between the APL-treated (Figure 7A-B,G) and
control groups (Figure 7A-B,E).
GFAP immunoreactivity in the ipsilateral and contra-
lateral sides of the spinal cord was higher on day 10
post-CCI compared to day 30 post-CCI within the
three treatment groups, but there were no significant
differences between groups on each of the tested days
(Figure 7C-D,H-J).Figure 6 Analysis of M1 and M2-like macrophages in the injured nerv
and (B) Iba-1+ and Arginase + cells (M2 macrophages) at 10 and 30 days p
APL-treated and control rats (n = 3 per group; mean ± SEM; two-way ANOVImmunization with cyclo-(87-99)[A91,A96]MBP87-99 increased
splenic regulatory T cells in the nerve-injured rats at 10 days
post-CCI
Previous reports showed that treatment with antagon-
istic APLs can induce immunosuppressive regulatory
T cells [20]. To investigate the effect of immunization
with cyclo-(87-99)[A91, A
96]MBP87-99 on the prevalence
of Treg cells in the spleen and lymph nodes, we used
flow cytometric analysis at day 10 and 30 post-CCI
(Figure 8). To identify regulatory T cells, we first gated
CD4+ cells (Figure 8B) out of lymphocyte singlets
(Figure 8A) in a total population of cells and then fur-
ther gated for CD25+ and FoxP3+ cells (Figure 8C).
We found that the percentage of Treg cells in the
spleen at 10 days post-CCI was significantly increased
(P < 0.01) in the APL-treated group compared to the
MBP-treated and control rats (Figure 8C-D). No sig-
nificant differences between treatment groups were
seen in the spleen at 30 days post-CCI (Figure 8D, left) or
in the lymph nodes at any time point analyzed (Figure 8D,
right).e. The percentage of (A) ED1+ and iNOS+ cells (M1 macrophages)
ost-CCI in the LSN. *P < 0.05 represents a significant difference between
A with Tukey’s multiple comparison test).
Figure 7 Immunohistochemistry of microglia and astrocytes in the lumbar spinal cord following CCI and immunization. The percentage
of Iba-1+ area density in the dorsal and ventral lumbar spinal cord at 10 days (A) and at 30 days (B) post-CCI and the percentage of GFAP+ area
density in the dorsal and ventral lumbar spinal cord at 10 days (C) and at 30 days (D) post-CCI. Representative images of Iba-1+ cells in the spinal
cord of the control (E), MBP-treated (F), APL-treated (G), and GFAP+ cells in the spinal cord of the control (H), MBP-treated (I), and APL-treated
(J) rats. +P < 0.05 and ++P < 0.01 represent significant differences between the MBP-treated and control rats, and **P < 0.01 and ****P < 0.0001
indicate significant differences between MBP- and APL-treated rats at 30 days post-CCI (n = 4 per group; mean ± SEM; two-way ANOVA with
Tukey’s multiple comparison test).
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[A91, A
96]MBP87-99 on cytokine expression following CCI
To test the effect of immunization with MBP87-99 and
cyclo-(87-99)[A91, A
96]MBP87-99 on cytokine expression
in the serum and relevant nervous system tissues, we
used a multiplex cytokine assay. In the injured left sci-
atic nerve, the cytokines IL-2, IL-4, IL-7, TNF-α, IFN-γ,granulocyte colony stimulating factor (G-CSF), erythro-
poietin (EPO), IL-17A, IL-13, and IL-12 were signifi-
cantly (P < 0.05 to 0.001) reduced, whereas the cytokines
IL-6, keratinocyte chemo attractant/growth-related onco-
gene (GRO/KC), macrophage colony stimulating factor
(M-CSF), and monocyte chemoattractant protein-1 (MCP-1)
were significantly (P < 0.05 to 0.0001) increased in at least
Figure 8 (See legend on next page.)
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Figure 8 Flow cytometry analysis of CD4+ CD25+ FoxP3+ expressing Treg cells in the spleen and lymph nodes following CCI and
immunization. (A) Representative forward scatter (FSC) vs. side scatter (SSC) plot showing the acquired events and lymphocyte gate from rat
spleen. (B) Representative histogram of counts vs. CD4+ cell population selected for further gating. (C) Representative dot plots of Treg cells in
the spleen of the control (left), MBP-treated (middle), and APL-treated (right) rats at 10 days post-CCI. (D) The percentage of CD4+ CD25+ FoxP3+
cells in the spleen and lymph nodes at 10 and 30 days post-CCI. **P < 0.01 indicates significant differences between APL-treated and MBP-treated
and control rats at 10 days post-CCI (n = 4 per group; mean ± SEM; two-way ANOVA with Tukey’s multiple comparison test).
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significant differences were found in IL-1α, IL-1β, IL-5, IL-
10, IL-18, macrophage inflammatory protein (MIP)-3a, reg-
ulated on activation normal T cell expressed and secreted
(RANTES), granulocyte macrophage colony stimulating
factor (GM-CSF), and vascular endothelial growth factor
(VEGF) in the injured nerve of all treatments groups com-
pared to the uninjured nerve (Figure 9A). In the ipsilat-
eral DRG, the cytokines IL-5, IL-10, IL-12, GM-CSF,
and IL-17A were significantly reduced (P < 0.05 to
0.001), whereas IL-2, IL-6, M-CSF, RANTES, and TNF-
α (P < 0.001) were significantly increased in at least one
of the treatment groups relative to the uninjured DRG.
The cytokines IL-1, IL-4, IL-7, IL-13, IL-18, MIP-3a,
GRO/KC, G-CSF, M-CSF, VEGF, IFN-γ, EPO, and
MCP-1 in the ipsilateral DRG in all treatment groups
were not significantly changed compared to the unin-
jured DRG (Figure 9B). In the spinal cord, concentrations
of GRO/KC (P < 0.0001), RANTES, and EPO (P < 0.05 to
0.01) were significantly increased in at least one of the
treatment groups relative to the uninjured spinal cord. All
other cytokines were not significantly changed in the
spinal cord of the treated rats as compared to the spinal
cord of the uninjured rats (Figure 9C). In the serum, there
was no significant difference in any of the cytokines tested
in all treatment groups relative to the serum of normal
rats (Figure 9D). Interestingly, the concentrations of IL-1α
(Figure 10A) and IL-β (Figure 10B) in the injured nerve of
MBP-treated rats significantly increased (IL-1α P = 0.02
and IL-1β P = 0.04; one-way ANOVA followed by Dunnet’s
multiple comparison test with adjusted P value) compared
to APL-treated rats, but not compared to the control CFA-
treated rats. There were no statistically significant differ-
ences between APL-treated and control rats in any of the
cytokines tested.
Discussion
The protective effects of antagonistic myelin-derived
APLs through T cell modulation have been demon-
strated in several models of autoimmune disease and
spinal cord injury [18,24,38,39], suggesting a potential
use in animal models of neuropathic pain. Here, we
investigated the effects of active immunization with cyclic
MBP87-99 (native peptide) and cyclo-(87-99)[A
91,A96]
MBP87-99 (APL) on pain sensitivity and neuroinflammation
following peripheral nerve injury in rats. We demonstratethat immunization with cyclo-(87-99)[A91,A96]MBP87-99
reduces mechanical pain hypersensitivity in the ipsilat-
eral hindpaws in association with reduced T cell infiltra-
tion at the site of injury, increased presence of M2
macrophages in the injured nerve, unaltered microglial
activation in the ipsilateral lumbar spinal cord, and in-
creased prevalence of splenic Treg cells. In agreement
with these findings, MBP-derived APLs have been
shown to modulate inflammatory responses towards an
anti-inflammatory mechanism [32] as well as to in-
crease Treg cells in previous studies [21]. Our result of
reduced mechanical allodynia in rats immunized with
cyclo-(87-99)[A91,A96]MBP87-99 is consistent with our
previous report that immunization with the same APL
significantly reduced mechanical allodynia in Lewis rats
with EAE [24]. In addition, immunization with the na-
tive peptide of MBP induced some mechanical allodynia
in the sham-operated rats. A recent study by Liu et al.
indicates MBP as a novel mediator of pain, as adminis-
tration of MBP69-86 or MBP84-104 peptides into naïve
nerve produced robust mechanical allodynia with an
associated increase in immune cell trafficking and anti-
gen presentation in the injected nerve. These effects
were considerably reduced in T cell-deficient nude rats,
indicating the involvement of T cells in MBP-mediated
pain [28]. Although we used a different epitope of MBP,
it may have contributed to the mechanical pain hyper-
sensitivity exhibited by the sham-operated rats in our
study. A previous work demonstrated that cyclo-MBP87-99
induces, while the antagonistic APLs cyclo-(91-96)[Ala96]
MBP87-99 and cyclo-(87-99)[Arg
91,Ala96]MBP87-99, inhibit
T cell proliferation in an in vitro-generated CD4+ T cell
line [23]. This suggests that immunization with MBP may
have caused recruitment of MBP-specific T cells to the in-
jured nerve. Conversely, such recruitment might have
been suppressed in APL-treated rats. Indeed, following
peripheral nerve injury matrix metalloproteinases pro-
mote peripheral myelin damage through degradation of
endogenous MBP, as well as macrophage infiltration and
central glia activation, thus contributing to mechanical
allodynia [27]. The repeated exposure of MBP epitopes
caused by the injury-induced MBP degradation leads to
the formation of MBP-specific T cell clones and a self-
sustaining immune reaction [28], which may be further
facilitated by immunization with MBP and inhibited by
immunization with APL.
Figure 9 Bio-plex analysis of cytokine expression profile in the nervous tissue and serum at 10 days post-CCI. Heat maps illustrating the
summary of fold change expression of cytokines in the (A) LSN, (B) left DRG, (C) spinal cord, and (D) serum of immunized nerve-injured rats compared
to control uninjured naïve rats at 10 days post-CCI. Yellow asterisks indicate significant differences in cytokine concentrations in treatment
groups as compared to the uninjured control group (n ≥ 4 per group; one-way ANOVA with Dunnet’s multiple comparison test compared to
the uninjured group).
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Figure 10 IL-1α and IL-β profile in the injured sciatic nerve at 10 days post-CCI. The concentrations of IL-1α (A) and IL-1β (B) in the LSN of
immunized nerve-injured rats at 10 days post-CCI. *P ≤ 0.05 indicates a significant difference between MBP- and APL-treated rats (n = 6 per group;
mean ± SEM; one-way ANOVA with Dunnet’s multiple comparison test compared to the APL-treated group).
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ciated with the development of pain hypersensitivity,
and animals lacking functional T cells have reduced pain
responses following peripheral nerve injury [5,6]. In ac-
cordance with this, we found that T cell infiltration to
the injured nerve was lower in rats immunized with
cyclo-(87-99)[A91,A96]MBP87-99 at 10 days post-CCI,
which also showed reduced mechanical pain hypersensi-
tivity. APLs can act as partial T cell agonists and thereby
result in either T cell anergy (functional incapacity of T
cell response to antigen) [40], down-regulation of ef-
fector T cells [41,42], or mediate bystander suppression
through the generation of Treg cells [20]. Thus, the
above mechanisms may be involved in the decreased T
cell infiltration into the injured nerve, and the lessened
mechanical allodynia in the APL-treated nerve-injured
rats. Although the dynamics of T cell infiltration into the
injured nerve differed among the treatment groups, T
cell numbers in the injured nerve were considerably
higher relative to the uninjured nerve in all the groups.
However, we found a significant increase in T cell counts
in the control rats at 10 days post-CCI and in the MBP-
treated rats at 30 days post-CCI when compared to
APL-treated rats. Indeed, a previous study demonstrated
that T cells infiltrate the injured nerve after CCI in in-
creasing numbers up to 21 days post-CCI followed by a
gradual reduction towards 40 days post-CCI in Lewis
rats [6]. Since MBP is expressed in both the peripheral
and central nervous system, nerve injury may have ex-
posed cryptic MBP epitopes [28] resulting in continuous
activation of MBP-specific T cells over time. This may
explain the pronounced increase in T cell infiltration in
MBP-treated rats at 30 days post-CCI. Although the ac-
tivation of T cells in the dorsal spinal cord following per-
ipheral nerve injury has been implicated in neuropathic
pain [5,43], significant numbers of T cells and differences
between treatment groups in the spinal cord and DRGs
were not seen in this study. Previous studies have dem-
onstrated that immunization with APLs increase Tregcells and mediate bystander suppression in animal
models of EAE [20]. We previously showed that Treg
cell expansion reduced mechanical pain hypersensitivity
following CCI [13]. Our current study shows a signifi-
cant elevation of Treg cells in the spleen of APL-treated
nerve-injured rats at 10 days post-CCI. Although the
antigen specificity and functional activity of these Treg
cells is unknown, increased splenic Treg cells in the
cyclo-(87-99)[A91,A96]MBP87-99-treated group may have
conferred a beneficial effect on neuropathic pain behav-
ior. The mechanism by which this is accomplished is
unclear but may be due to suppression of conventional
antigen-specific T cells and killing T cells by granzyme-
dependent or perforin-dependent mechanisms [44] in the
periphery.
ED1+ macrophage reactivity in the injured nerve was
significantly reduced in cyclo-(87-99)[A91,A96]MBP87-99-
treated animals. Indeed, macrophage depletion has been
shown to attenuate pain hypersensitivity in some neuro-
pathic pain models [34,36]. Recently however, the con-
cept of formation of definitive functional macrophage
phenotypes has emerged. M1 activity is associated with
inhibition of cell proliferation and tissue damage (pre-
dominantly pro-inflammatory), while M2 activity is
linked to the promotion of cell proliferation and tissue
repair (predominantly anti-inflammatory) [37,45,46].
Therefore, we further investigated the effect of treatment
on the prevalence of M1 and M2 macrophages in the in-
jured nerve. ED1+ cells and Iba-1+ cells were visible
along the length of the nerve; however, iNOS+ macro-
phages were mostly localized at the site of injury, and
Arginase+ cells were localized in the intact nervous tis-
sue and towards the periphery of the nerve. This kind of
cellular pattern clearly suggests the pro-inflammatory
nature of M1 macrophages being responsible for clearing
debris at the site of injury and the anti-inflammatory
role of M2 macrophages in protecting the surrounding
tissue [46]. Interestingly, we observed a mixed infiltra-
tion of M1 and M2 macrophages in the injured nerve at
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M1 macrophages seemed to be less prevalent at 10 days
post-CCI and increased over time, albeit there was no
significant difference between the treatment groups. A
previous study has investigated the expression of M1
and M2 markers following axotomy in the sciatic nerve
in C57BL/6 mice [45]. They did not find any of the M1
markers including iNOS in the nerve at any time point
investigated, which is contrary to our results. However,
Turtzo et al. demonstrated characteristic expression of
M1 and M2 markers in the brain following traumatic
brain injury (TBI) in female Wistar rats [46]. Two other
studies of TBI in mice have reported a mixed M1 and
M2 response, in which M2 response peaked at 5 days
post-CCI and returned to baseline by 2 weeks [47,48].
Similarly, a study of mice with spinal cord injury has
shown expression of distinct M1 and M2 markers with
M1 phenotype dominating the lesion site and nearby
spared tissue and the M2 response lasting only for 3 to
7 days post-injury [37], whereas in our study, the Argi-
nase +M2 response continued until 30 days post-CCI.
These studies illustrate the diversity in macrophage acti-
vation across species and experimental models.
A previous study has demonstrated that immunization
of spinal cord-injured mice with myelin oligodendrocyte
glycoprotein (MOG)-derived altered peptide resulted in
a higher number of recruited monocyte-derived macro-
phages with anti-inflammatory properties and improved
recovery [49]. Herein, we show that treatment with cyclo-
(87-99)[A91,A96]MBP87-99 has significantly increased the
presence of M2 macrophages at 30 days post-CCI, sug-
gesting a possible immunomodulatory mechanism of APL
towards an M2-mediated phase in the latter stages follow-
ing peripheral nerve injury. M2 macrophages are capable
of resolving inflammation and promoting Th2 immune re-
sponses [50]. Previous studies reported inhibition of EAE,
suppression of Th17 cell proliferation, upregulation of
Th2 and Treg cells, reduced macrophage/microglia activa-
tion, and increased Treg cell gene expression such as
GATA3 and FoxP3 in mice following adoptive transfer of
M2 macrophages [51,52]. Such protective mechanisms of
M2 macrophages may have contributed to the reduced
neuroinflammation and mechanical allodynia in the APL-
treated rats.
Microglial activation in the spinal cord plays a key role
in driving the development and maintenance of pain
hypersensitivity following peripheral nerve damage, and
pharmacological inhibition of microglial activation has
been shown to attenuate neuropathic pain [53,54]. In
this study, the MBP-treated rats demonstrated signifi-
cantly increased microglial activation in the ipsilateral lum-
bar spinal cord compared to the cyclo-(87-99)[A91,A96]
MBP87-99-treated and control rats. However, despite a sig-
nificant difference in pain hypersensitivity between APL-treated and control rats, there was no significant difference
in their spinal microglial activation suggesting that micro-
glia do not play a key role in ameliorating mechanical pain
hypersensitivity in APL-treated nerve-injured rats. Other
studies have also reported no correlation between neuro-
pathic pain behaviors and microglial activation. For ex-
ample, Colburn et al. demonstrated that neuropathic pain
behaviors did not correlate with spinal microglial responses
following nerve injury; in some rats, pain hypersensitivity
existed in the apparent absence of microglial activation,
and conversely, profound microglial activation was occa-
sionally associated with a lack of pain hypersensitivity [55].
Likewise, perineural application of the local anesthetic
bupivacaine markedly reduced microglia responses follow-
ing spinal nerve cryoneurolysis without ameliorating pain
hypersensitivity [55]. Other models of neuropathic pain,
such as chemotherapy-induced peripheral neuropathy [56]
and central pain due to oligodendrocyte ablation [57] have
shown no correlation between microglial activation and
pain responses. Similarly, several studies have demon-
strated the presence of pain hypersensitivity in the absence
of astrocyte activation [57,58], in line with the lack of spinal
astrocyte activation in the present study. For example, a
previous study has shown no change in GFAP-positive cells
and GFAP protein levels in the ipsilateral dorsal horn of
the spinal cord following CCI [59]. Robust mechanical pain
hypersensitivity was elicited in oligodendrocyte-ablated
mice without significant activation of astrocytes [57]. A
preconditioning nerve lesion inhibited mechanical pain
hypersensitivity following subsequent neuropathic injury
without altering either spinal microglial or astrocyte activa-
tion [60]. It is plausible that our treatments induced a
change in as yet unknown distinct phenotypes of glial cells
without altering the total expression of activation markers
in the spinal cord.
Treatment with APLs has also been shown to modu-
late the cytokine response in mice with EAE [32]. For
example, Katasara et al. have previously demonstrated
increased concentrations of anti-inflammatory cytokines
IL-4 and IL-10 in SJL/J mice following intradermal
immunization with MBP-derived APL conjugated to re-
duced mannan [32]. We found an altered expression of
several cytokines in the injured nerve, ipsilateral DRG,
spinal cord, and serum in all treatment groups as com-
pared to control naïve animals. It is noteworthy that the
profile of some cytokines was completely different in
each of the different sites along the pain pathway. A sur-
prising finding was a reduction in the expression of sev-
eral pro-inflammatory cytokines in the nervous system
tissues of nerve-injured animals. Turtzo et al. has also
reported a similar pattern of cytokine expression with
increased cytokine levels in the contralateral side in
Wistar rats following TBI [46]. In fact, unilateral peripheral
nerve injury has been shown to affect the contralateral side
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expression has been observed in the contralateral
nerve following CCI in mice [63]. The later study
identified the involvement of N-methyl-D-aspartate
(NMDA) receptor signaling as one underlying mechan-
ism, since intraperitoneal administration of NMDA antag-
onist MK-801 completely blocked the contralateral gene
expression of IL-1β and MCP-1 following CCI [63]. It is
logical to assume that differences in cytokine expression
between studies may result from differences in species,
strain, injury type, testing time, tissue analyzed, and
sampling and processing methods [64].
In the current study, we observed that MBP-treated
rats had significantly increased IL-1α and IL-1β con-
centrations in the injured nerve analyzed at 10 days
post-CCI compared to cyclo-(87-99)[A91,A96]MBP87-99-
treated rats. The IL-1 family consists of IL-1α and IL-
1β, which bind to the IL-1-type 1 receptor and the IL-1
receptor accessory protein [65]. IL-1β is one of the pre-
dominant pro-inflammatory cytokines released follow-
ing injury [66] and is known to be released by
microglia and macrophages [67]. The involvement of
IL-1 in neuropathic pain has been previously shown
[68,69], including its ability to increase neuronal excit-
ability [70]. It has been reported that the intrathecal ad-
ministration of IL-1β induces mechanical and thermal
hyperalgesia in rats [71,72], whereas intrathecal admin-
istration of IL-1 receptor antagonists (IL-1ra) alleviated
hyperalgesia in CFA-induced inflammatory pain [73].
In addition, deletion of IL-1 receptors and overexpres-
sion of IL-1ra ameliorated neuropathic pain behavior in
transgenic mice with spinal nerve transection [74].
Thus, upregulation of IL-1β by MBP87-99 may have
played a role in the mechanical pain hypersensitivity in
MBP-treated rats in the present study.
Conclusions
The present data suggest that immune deviation by ac-
tive immunization with a non-encephalitogenic myelin-
derived APL mediates an analgesic effect in neuropathic
animals. The exact analgesic mechanisms of the APL
cyclo-(87-99)[A91,A96]MBP87-99 in nerve-injured animals
are not known, however, modulating neuroinflammation
by decreased infiltration of T cells and macrophages, upreg-
ulation of a M2 macrophage-dominant anti-inflammatory
response and upregulation of splenic regulatory T cells are
all possible explanations. These findings support the poten-
tial application of immunization with myelin-derived APL
for the treatment of peripheral neuropathic pain.
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